BIIB Aug 2022 195.000 put
| Previous close | 0.1500 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 195.00 |
| Expiry date | 2022-08-05 |
| Day's range | 0.1000 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
- Yahoo Finance Video
Health care bill ‘most aggressive action’ on drug pricing: Analyst
Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.
- Motley Fool
Good News for Retirees: Lower Medicare Part B Premiums Could Be Coming
Millions of Americans are eagerly waiting to find out how much their Social Security cost-of-living adjustment (COLA) will be for 2023. One big reason why that's the case is that Social Security's COLA calculation doesn't include Medicare Part B premiums. You might wonder how Medicare Part B premiums could possibly decline.
- GlobeNewswire
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary endpointBiogen is also evaluating litifilimab in systemic lupus erythematosus through the Phase 3 TOPAZ studies and plans to initiate a pivotal study in CLE later this yearBiogen is advancing two lupus therapies in Phase 3 trials to address this chronic autoimmune disease CAMBRIDGE, Mass., July 28, 2022 (
